Most recently, she served as President and CEO of InCarda Therapeutics, Inc., a clinical stage cardiovascular company for which she raised ~$120M in venture financing and led the lead product from pre-clinical stage to Phase 3 initiation. She is currently Executive Chairman (formerly CEO) of ProterixBio, Board Chair of Bloom Science and Emm Technology, and serves on the boards of CareDx, Inc., Voyager Therapeutics, Inc., the MIT Board of Trustees, and the Biotechnology Innovation Organization (BIO), where she is Vice Chair of the Emerging Companies Section and serves on the Executive Committee.
Formerly, she was a partner at New Science Ventures and served on the boards of Cocoon Biotech, PerceptiMed and Paradigm Diagnostics. Previously she was SVP and President of the Industrial Products Division at Intrexon Corporation. Prior to Intrexon, she held several roles at Gilead Sciences, including leading the Clinical Operations, Alliance Management, and Commercial Strategic Planning groups. Prior to Gilead, she was VP of Corporate Planning at Affymetrix and Acting Chief Operating Officer for the International Genomics Consortium. Prior to Affymetrix, Dr. Colón was an engagement manager with McKinsey & Co., where she served clients in health care, biotech, high tech and venture capital.
She received her Ph.D. from the Massachusetts Institute of Technology and a B.S. degree from the University of Pennsylvania, both in chemical engineering. Dr. Colón is a native of San Juan, Puerto Rico.